See the DrugPatentWatch profile for Umeclidinium
The price of Umeclidinium Vilanterol Ellipta, commonly known by the brand name Trelegy Ellipta, varies depending on factors such as insurance coverage, pharmacy, and geographic location.
What is Trelegy Ellipta used for?
Trelegy Ellipta is a combination inhaler containing three medications: umeclidinium, vilanterol, and fluticasone furoate. It is prescribed for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and/or emphysema [1]. It is also used to reduce exacerbations of COPD [1]. Additionally, Trelegy Ellipta is indicated for the maintenance treatment of asthma in patients aged 12 years and older [1].
How much does Trelegy Ellipta cost without insurance?
Without insurance, the retail price for a 30-day supply of Trelegy Ellipta can range significantly, often falling between $300 and $500, and sometimes exceeding $600 [2][3]. This price can be influenced by the specific dosage and the number of inhalations per device.
Can I get assistance with the cost of Trelegy Ellipta?
Several options may be available to reduce the out-of-pocket cost for Trelegy Ellipta. Patients with commercial insurance may be eligible for savings cards or co-pay assistance programs offered by the manufacturer, GSK [2][4]. Eligibility requirements and the amount of savings can vary. For eligible commercially insured patients, savings can bring the cost down to as low as $10 per prescription [4]. Medicare patients may have different assistance options.
Are there generic versions of Trelegy Ellipta available?
As of now, there are no generic versions of Trelegy Ellipta on the market [5]. The drug is protected by patents, and generic alternatives typically become available after patent expiration.
When do the patents for Trelegy Ellipta expire?
Patent information for pharmaceuticals is complex and can involve multiple patents covering different aspects of the drug, such as its composition, method of use, and manufacturing. According to DrugPatentWatch.com, the exclusivity and patent landscape for umeclidinium/vilanterol/fluticasone furoate can be extensive, with various patents potentially expiring at different times, impacting when generic competition might emerge [5]. Users seeking detailed information on specific patent expiration dates and potential generic entry timelines can refer to resources like DrugPatentWatch.com [5].
How does Trelegy Ellipta compare to other COPD or asthma inhalers?
Trelegy Ellipta is a triple therapy inhaler, combining an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta2-adrenergic agonist (LABA). This combination targets multiple pathways involved in airway inflammation and constriction. Other COPD and asthma treatment options include dual therapy inhalers (ICS/LABA or LAMA/LABA) and single-agent therapies [6]. The choice of inhaler depends on the severity of the condition, individual patient needs, and response to treatment.
What are the common side effects of Trelegy Ellipta?
Common side effects associated with Trelegy Ellipta include nasopharyngitis (common cold symptoms), headache, back pain, chest pain, increased blood pressure, and oral thrush (candidiasis) [1]. Patients are advised to rinse their mouth with water after each use to help prevent oral thrush.
Sources:
1. GSK. Trelegy Ellipta (umeclidinium, vilanterol, and fluticasone furoate) prescribing information.
2. GoodRx. Umeclidinium-vilanterol-fluticasone furoate (trelegy ellipta) prices, coupons, and patient assistance programs.
3. Cost Plus Drugs. Umeclidinium-vilanterol-fluticasone furoate.
4. GSK. Patient assistance and savings programs.
5. DrugPatentWatch. Umeclidinium vilanterol fluticasone furoate patent landscape.
6. National Institutes of Health. COPD medications.